Gyre Therapeutics, Inc.
GYRE
$8.11
$0.354.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 442.00K | 2.70M | -99.00K | 1.12M | 3.53M |
| Total Depreciation and Amortization | 641.00K | 535.00K | 471.00K | 454.00K | 228.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.48M | 2.26M | 685.00K | 1.85M | 1.05M |
| Change in Net Operating Assets | -476.00K | -5.63M | -3.82M | -1.70M | -10.30M |
| Cash from Operations | 2.09M | -129.00K | -2.76M | 1.73M | -5.49M |
| Capital Expenditure | -256.00K | -122.00K | 65.00K | -693.00K | -1.46M |
| Sale of Property, Plant, and Equipment | 18.00K | 1.00K | 138.00K | -5.00K | 218.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.80M | 2.09M | -2.21M | -1.69M | -7.04M |
| Cash from Investing | -3.04M | 1.97M | -2.00M | -2.39M | -8.27M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 24.03M | 1.47M | 1.33M | 374.00K | 275.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.68M | -121.00K | -367.00K | -50.00K | -119.00K |
| Cash from Financing | 22.35M | 1.34M | 964.00K | 324.00K | 156.00K |
| Foreign Exchange rate Adjustments | 49.00K | 50.00K | -255.00K | 106.00K | -78.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.45M | 3.23M | -4.05M | -231.00K | -13.69M |